MetaCap

BioLineRx (BLRX) vs Scienture (SCNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioLineRx is the larger company by market cap ($4.8 million vs $4.1 million), about 1.2 times the size, while Scienture is growing revenue faster (+215.9% vs -95.9%). BioLineRx converts more of its revenue into profit, with a net margin of -171.7% versus -9618.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLRX-56.29%SCNX-44.85%
+3%-28%-59%
Oct 7, 20261 yearNov 20, 2026
BLRX-56.50%SCNX-39.42%
+3%-28%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLRX versus SCNX key metrics
MetricBLRXSCNX
Share price$0.9639$2.28
Market cap$4.80M$4.07M
1-day change-8.20%-6.45%
YTD return-65.20%—
1-year return-70.34%—
5-year return-99.07%—
EPS (TTM)$0.00$-51.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.18M$431.61K
Revenue growth (YoY)-95.92%+215.87%
Net income (latest FY)$-2.03M$-41.51M
Gross margin80.51%76.80%
Operating margin-871.78%-9867.92%
Net margin-171.69%-9618.03%
52-week high$3.95$18.75
52-week low$0.78$2.00
Distance from 52-week high-75.60%-87.85%
Analyst consensusnonebuy
Avg. price target upside+2182.39%+1546.25%
Average volume23.43K156.51K
Shares outstanding4.98M1.79M
Employees204
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BioLineRx is more profitable, keeping -171.7 cents of every revenue dollar as net income versus -9618.0 cents for Scienture.
  • Scienture grew revenue faster in its latest fiscal year (+215.87% vs -95.92%).

About BioLineRx

BLRX stock →

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Scienture

SCNX stock →

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

BLRX vs SCNX FAQ

Which is bigger, BioLineRx or Scienture?

BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.07M for Scienture (SCNX).

Are BioLineRx and Scienture in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons